Atopic Dermatitis Clinical Trials in Los Angeles, California

12 studies are recruiting for atopic dermatitis in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

   This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Investigational Site, Los Angeles, California

   Locations

   80 in total

   Run by

   Apogee Therapeutics, Inc.

   See if you can join NCT07003425 on ClinicalTrials.gov

2. This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

   The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. …

   Stage

   Not phased

   Ages

   12 and older

   Site

   Dermatology Research Associates - Los Angeles- Site Number : 8400020, Los Angeles, California

   Locations

   82 in total

   Run by

   Sanofi

   See if you can join NCT07290803 on ClinicalTrials.gov

3. A Study Evaluating TRIV-573 in Atopic Dermatitis

   The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573. Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo). The study duratio…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Triveni Bio Site #4, Los Angeles, California

   Locations

   17 in total

   Run by

   Triveni Bio

   See if you can join NCT07782333 on ClinicalTrials.gov

4. A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

   The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema is a condition which can cause dryness, itching, and redness of your skin. The study is seeking partic…

   Stage

   Phase 3

   Ages

   12 and older

   Site

   California Allergy & Asthma Medical Group, Los Angeles, California

   Locations

   32 in total

   Run by

   Pfizer

   See if you can join NCT07783425 on ClinicalTrials.gov

5. Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

   This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic dia…

   Stage

   Not phased

   Ages

   12 to 89

   Site

   James Y. Wang MD, Inc, Los Angeles, California

   Locations

   13 in total

   Run by

   Castle Biosciences Incorporated

   See if you can join NCT07645820 on ClinicalTrials.gov

6. A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

   The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. A…

   Stage

   Phase 2

   Ages

   18 to 64

   Site

   Metropolis Dermatology - DTLA, Los Angeles, California

   Locations

   42 in total

   Run by

   Pfizer

   See if you can join NCT07216027 on ClinicalTrials.gov

7. Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

   This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

   Stage

   Phase 2

   Ages

   18 to 100

   Site

   Novartis Investigative Site, Los Angeles, California

   Locations

   105 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06947993 on ClinicalTrials.gov

8. A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

   This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Metropolis Dermatology, Los Angeles, California

   Locations

   85 in total

   Run by

   Apollo Therapeutics Ltd

   See if you can join NCT07599813 on ClinicalTrials.gov

9. A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

   The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

   Stage

   Phase 2

   Ages

   18 to 74

   Site

   Inmagene Site 23, Los Angeles, California

   Locations

   30 in total

   Run by

   Inmagene LLC

   See if you can join NCT07037901 on ClinicalTrials.gov

10. A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

    This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD). The study will compare three dose levels of ENV-294 with placebo administered for 12 weeks. Participants will undergo screening, receive s…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Enveda Investigative Site, Los Angeles, California

    Locations

    9 in total

    Run by

    Enveda Therapeutics

    See if you can join NCT07643766 on ClinicalTrials.gov

11. Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

    This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    California Allergy and Asthma Medical Group, Los Angeles, California

    Locations

    16 in total

    Run by

    Oneness Biotech Co., Ltd.

    See if you can join NCT06397911 on ClinicalTrials.gov

12. Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

    The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

    Stage

    Not phased

    Ages

    12 and older

    Site

    Galderma Investigational Site 7099, Los Angeles, California

    Locations

    108 in total

    Run by

    Galderma R&D

    See if you can join NCT06988605 on ClinicalTrials.gov